grant
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
Organization WAKE FOREST UNIVERSITYLocation WINSTON-SALEM, UNITED STATESPosted 20 May 2022Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY20252-(3-pyridinyl)-1-hydroxyethylidenebisphosphonateAgeAgreementAmericanAnimal ModelAnimal Models and Related StudiesAreaBiologicalBiological MarkersBisphosphonatesBody Weight decreasedBone DensityBone Mineral DensityBone ResorptionBone-Derived Transforming Growth FactorCAT scanCT X RayCT XrayCT imagingCT scanCTXCYCLO-cellCarloxanCausalityCell BodyCell Communication and SignalingCell SignalingCellsCiclofosfamidaCiclofosfamideCicloxalClafenClapheneClinicalClinical ManagementClinical PathologyComputed TomographyCoxaCycloblastinCycloblastineCyclophosphamCyclophosphamideCyclophosphamidumCyclophosphanCyclophosphaneCyclophosphanumCyclostinCyclostineCytophosphanCytophosphaneCytoxanDEXADXADataDistalDual-Energy X-Ray AbsorptiometryDual-Energy Xray AbsorptiometryEffectiveness of InterventionsEndoxanEndoxanaEnduxanEtiologyFatsFatty acid glycerol estersFemurFosfaseronFractureFracture due to osteoporosisGDF-8GDF8GDF8 geneGastrectomyGenoxalGenuxalGrowth Differentiation Factor 8 GeneGrowth/Differentiation Factor 8Health BenefitHipHip region structureHumanInfiltrationInterventionIntervention TrialInterventional trialIntracellular Communication and SignalingKnowledgeLeannessLedoxinaMSTNMeasuresMetabolicMilk Growth FactorMitoxanModern ManMonitorMorbid ObesityMuscleMuscle AtrophyMuscle TissueMuscular AtrophyMusculoskeletalNeckNeosarOPGLObesityOperative ProceduresOperative Surgical ProceduresOralOsteoclastic Bone LossOsteoclastsOsteoporosis with fractureOsteoporotic fractureOutcome AssessmentParticipantPatientsPhysical FunctionPhysical PerformancePlacebosPlatelet Transforming Growth FactorPositionPositioning AttributeProceduresProcytoxPublic HealthRANKLRadialRadiusRandomizedRecommendationReportingRisedronateSecondary toSendoxanSevere obesitySham TreatmentSignal TransductionSignal Transduction SystemsSignalingSiteSkeletonSocietiesSpinal ColumnSpineSurgicalSurgical InterventionsSurgical ProcedureSyklofosfamidTGF BTGF-betaTGF-βTGFbetaTGFβTNFSF11TNFSF11 geneTask PerformancesTestingThickThicknessThinnessTomodensitometryTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneUnited StatesVertebral columnWalkingWeight LossWeight ReductionX-Ray CAT ScanX-Ray Computed TomographyX-Ray Computerized TomographyXray CAT scanXray Computed TomographyXray computerized tomographyZytoxanadiposityagesanimal databackbonebariatric surgerybio-imagingbio-markersbioimagingbiologicbiologic markerbiological signal transductionbiomarkerbiphosphonatebisphosphonatebody weight lossbonebone fracturebone lossbone turnovercatscancausationclinical practiceco-morbidco-morbiditycomorbiditycomputed axial tomographycomputer tomographycomputerized axial tomographycomputerized tomographycorpulencedensitydesigndesigningdiphosphonatedisease causationextreme obesityfracture riskgastric bandinggastric bypass surgerygastrointestinalgrowth-differentiation factor 8hRANKL2high riskimplantable gastric stimulation bandingimprovedinsightintervention designmid lifemid-lifemiddle agemiddle agedmidlifemodel of animalmouse modelmurine modelmuscle breakdownmuscle degradationmuscle deteriorationmuscle lossmuscle wastingmuscularmyostatinnon-contrast CTnoncontrast CTnoncontrast computed tomographynovelobesity surgeryosteoporosis associated fractureosteoporosis related fractureosteoporosis with pathological fracturepreservationprimary outcomeprospectiverandomisationrandomizationrandomly assignedsOdfsham therapyskeletalskeletonsstomach staplingsurgerytherapy designtreatment designtreatment grouptrial designweight loss surgerywork groupworking groupwt-loss
Description preview
PROJECT SUMMARY
Despite well recognized improvements in obesity-related comorbidities, mounting evidence implicates sleeve
gastrectomy (SG) in the onset of skeletal fragility. Bisphosphonate therapy reduces osteoporotic fracture risk
and may also be effective in minimizing bone loss associated with SG. Once-monthly oral risedronate is a
commonly…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click